Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 208

1.

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.

Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, Li CW, Kim T, Chang SS, Lee HH, Hsu JL, Wang HL, Kuo CW, Chang WC, Hadad S, Purdie CA, McCoy AM, Cai S, Tu Y, Litton JK, Mittendorf EA, Moulder SL, Symmans WF, Thompson AM, Piwnica-Worms H, Chen CH, Khoo KH, Hung MC.

Mol Cell. 2018 Aug 16;71(4):606-620.e7. doi: 10.1016/j.molcel.2018.07.030.

PMID:
30118680
2.

Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience.

Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT.

Clin Breast Cancer. 2018 Jul 10. pii: S1526-8209(18)30009-0. doi: 10.1016/j.clbc.2018.07.008. [Epub ahead of print]

PMID:
30077429
3.

Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.

Jackson DO, Trappey FA, Clifton GT, Vreeland TJ, Peace KM, Hale DF, Litton JK, Murray JL, Perez SA, Papamichail M, Mittendorf EA, Peoples GE.

Clin Immunol. 2018 Jul 17;195:28-35. doi: 10.1016/j.clim.2018.06.008. [Epub ahead of print]

PMID:
30025819
4.

Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System: Review of the Supporting Evidence.

Weiss A, King TA, Hunt KK, Mittendorf EA.

Surg Clin North Am. 2018 Aug;98(4):687-702. doi: 10.1016/j.suc.2018.03.005. Epub 2018 May 21. Review.

PMID:
30005768
5.

Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy.

Armer JM, Ballman KV, McCall L, Armer NC, Sun Y, Udmuangpia T, Hunt KK, Mittendorf EA, Byrd DR, Julian TB, Boughey JC.

Support Care Cancer. 2018 Jul 6. doi: 10.1007/s00520-018-4334-7. [Epub ahead of print]

PMID:
29980907
6.

Multidisciplinary Intraoperative Assessment of Breast Specimens Reduces Number of Positive Margins.

Tevis SE, Neuman HB, Mittendorf EA, Kuerer HM, Bedrosian I, DeSnyder SM, Thompson AM, Black DM, Scoggins ME, Sahin AA, Hunt KK, Caudle AS.

Ann Surg Oncol. 2018 Jun 26. doi: 10.1245/s10434-018-6607-2. [Epub ahead of print]

PMID:
29947001
7.

Long-Term Impact of Regional Nodal Irradiation in Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy.

Stecklein SR, Park M, Liu DD, Valle Goffin JJ, Caudle AS, Mittendorf EA, Barcenas CH, Mougalian S, Woodward WA, Valero V, Sahin AA, Yang WT, Shaitelman SF.

Int J Radiat Oncol Biol Phys. 2018 Jun 18. pii: S0360-3016(18)31007-1. doi: 10.1016/j.ijrobp.2018.06.016. [Epub ahead of print]

PMID:
29928946
8.

Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis.

Valachis A, Mamounas EP, Mittendorf EA, Hayashi N, Ishitobi M, Natoli C, Fitzal F, Rubio IT, Tiezzi DG, Shin HC, Anderson SJ, Hunt KK, Matsuda N, Ohsumi S, Totomi A, Nilsson C.

Cancer. 2018 Jul 15;124(14):2923-2930. doi: 10.1002/cncr.31518. Epub 2018 May 3.

PMID:
29723396
9.

Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma.

Alatrash G, Perakis AA, Kerros C, Peters HL, Sukhumalchandra P, Zhang M, Jakher H, Zope M, Patenia R, Sergeeva A, Yi S, Young KH, Philips AV, Cernosek AM, Garber HR, Qiao N, Weng J, St John LS, Lu S, Clise-Dwyer K, Mittendorf EA, Ma Q, Molldrem JJ.

Clin Cancer Res. 2018 Jul 15;24(14):3386-3396. doi: 10.1158/1078-0432.CCR-17-2626. Epub 2018 Apr 16.

PMID:
29661776
10.

Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.

Vreeland TJ, Litton JK, Qiao N, Philips AV, Alatrash G, Hale DF, Jackson DO, Peace KM, Greene JM, Berry JS, Clifton GT, Peoples GE, Mittendorf EA.

Clin Immunol. 2018 Jul;192:6-13. doi: 10.1016/j.clim.2018.03.010. Epub 2018 Mar 21.

PMID:
29574039
11.

Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target.

Khan M, Carmona S, Sukhumalchandra P, Roszik J, Philips A, Perakis AA, Kerros C, Zhang M, Qiao N, John LSS, Zope M, Goldberg J, Qazilbash M, Jakher H, Clise-Dwyer K, Qiu Y, Mittendorf EA, Molldrem JJ, Kornblau SM, Alatrash G.

Front Immunol. 2018 Jan 25;8:1975. doi: 10.3389/fimmu.2017.01975. eCollection 2017.

12.

Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).

Le-Petross HT, McCall LM, Hunt KK, Mittendorf EA, Ahrendt GM, Wilke LG, Ballman KV, Boughey JC.

AJR Am J Roentgenol. 2018 Mar;210(3):669-676. doi: 10.2214/AJR.17.18295. Epub 2018 Jan 30.

13.

A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity.

Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK.

NPJ Breast Cancer. 2017 Dec 6;3:49. doi: 10.1038/s41523-017-0052-4. eCollection 2017.

14.

Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer.

Weiss A, Chavez-MacGregor M, Lichtensztajn DY, Yi M, Tadros A, Hortobagyi GN, Giordano SH, Hunt KK, Mittendorf EA.

JAMA Oncol. 2018 Feb 1;4(2):203-209. doi: 10.1001/jamaoncol.2017.4298.

PMID:
29222540
15.

Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions.

Chavez-MacGregor M, Mittendorf EA.

Lancet Oncol. 2017 Dec;18(12):1568-1569. doi: 10.1016/S1470-2045(17)30844-6. Epub 2017 Nov 13. No abstract available.

PMID:
29146400
16.

Anatomy and Breast Cancer Staging: Is It Still Relevant?

Plichta JK, Campbell BM, Mittendorf EA, Hwang ES.

Surg Oncol Clin N Am. 2018 Jan;27(1):51-67. doi: 10.1016/j.soc.2017.07.010. Review.

PMID:
29132565
17.

Trends and variations in postmastectomy radiation therapy for breast cancer in patients with 1 to 3 positive lymph nodes: A National Cancer Data Base analysis.

Ohri N, Sittig MP, Tsai CJ, Hwang ES, Mittendorf EA, Shi W, Zhang Z, Ho AY.

Cancer. 2018 Feb 1;124(3):482-490. doi: 10.1002/cncr.31080. Epub 2017 Nov 7.

PMID:
29112227
18.

Expanding Implementation of ACOSOG Z0011 in Surgeon Practice.

Weiss A, Mittendorf EA, DeSnyder SM, Hwang RF, Bea V, Bedrosian I, Hoffman K, Adrade B, Sahin AA, Kuerer HM, Hunt KK, Caudle AS.

Clin Breast Cancer. 2018 Aug;18(4):276-281. doi: 10.1016/j.clbc.2017.10.007. Epub 2017 Oct 13.

PMID:
29100726
19.

Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells.

Shen H, Sun T, Hoang HH, Burchfield JS, Hamilton GF, Mittendorf EA, Ferrari M.

Semin Immunol. 2017 Dec;34:114-122. doi: 10.1016/j.smim.2017.09.002. Epub 2017 Sep 23. Review.

PMID:
28947107
20.

Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.

Gall VA, Philips AV, Qiao N, Clise-Dwyer K, Perakis AA, Zhang M, Clifton GT, Sukhumalchandra P, Ma Q, Reddy SM, Yu D, Molldrem JJ, Peoples GE, Alatrash G, Mittendorf EA.

Cancer Res. 2017 Oct 1;77(19):5374-5383. doi: 10.1158/0008-5472.CAN-16-2774. Epub 2017 Aug 17.

PMID:
28819024
21.

All HER2-Positive Tumors are not Created Equal.

Mittendorf EA, Chavez-MacGregor M.

Ann Surg Oncol. 2017 Nov;24(12):3471-3474. doi: 10.1245/s10434-017-6053-6. Epub 2017 Aug 16. No abstract available.

PMID:
28815451
22.

Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members.

Caudle AS, Bedrosian I, Milton DR, DeSnyder SM, Kuerer HM, Hunt KK, Mittendorf EA.

Ann Surg Oncol. 2017 Oct;24(10):2925-2934. doi: 10.1245/s10434-017-5958-4. Epub 2017 Aug 1.

PMID:
28766207
23.

Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer.

DeSnyder SM, Mittendorf EA, Le-Petross C, Krishnamurthy S, Whitman GJ, Ueno NT, Woodward WA, Kuerer HM, Akay CL, Babiera GV, Yang W, Lucci A.

Clin Breast Cancer. 2018 Feb;18(1):e73-e77. doi: 10.1016/j.clbc.2017.06.014. Epub 2017 Jul 10.

PMID:
28755879
24.

Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology.

Mittendorf EA, Chavez-MacGregor M, Vila J, Yi M, Lichtensztajn DY, Clarke CA, Giordano SH, Hunt KK.

Ann Surg Oncol. 2017 Nov;24(12):3502-3509. doi: 10.1245/s10434-017-6009-x. Epub 2017 Jul 19.

PMID:
28726077
25.

Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance).

Boughey JC, Ballman KV, McCall LM, Mittendorf EA, Symmans WF, Julian TB, Byrd D, Hunt KK.

Ann Surg. 2017 Oct;266(4):667-676. doi: 10.1097/SLA.0000000000002373.

PMID:
28657941
26.

Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer.

Akay CL, Albarracin C, Torstenson T, Bassett R, Mittendorf EA, Yi M, Kuerer HM, Babiera GV, Bedrosian I, Hunt KK, Hwang RF.

Breast J. 2018 Jan;24(1):28-34. doi: 10.1111/tbj.12829. Epub 2017 Jun 13.

PMID:
28608612
27.

Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System.

Chavez-MacGregor M, Mittendorf EA, Clarke CA, Lichtensztajn DY, Hunt KK, Giordano SH.

Oncologist. 2017 Nov;22(11):1292-1300. doi: 10.1634/theoncologist.2017-0116. Epub 2017 Jun 7.

PMID:
28592619
28.

4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells.

Harao M, Forget MA, Roszik J, Gao H, Babiera GV, Krishnamurthy S, Chacon JA, Li S, Mittendorf EA, DeSnyder SM, Rockwood KF, Bernatchez C, Ueno NT, Radvanyi LG, Vence L, Haymaker C, Reuben JM.

Cancer Immunol Res. 2017 Jun;5(6):439-445. doi: 10.1158/2326-6066.CIR-16-0364. Epub 2017 May 4.

29.

Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cells.

Kerros C, Tripathi SC, Zha D, Mehrens JM, Sergeeva A, Philips AV, Qiao N, Peters HL, Katayama H, Sukhumalchandra P, Ruisaard KE, Perakis AA, St John LS, Lu S, Mittendorf EA, Clise-Dwyer K, Herrmann AC, Alatrash G, Toniatti C, Hanash SM, Ma Q, Molldrem JJ.

J Biol Chem. 2017 Jun 16;292(24):10295-10305. doi: 10.1074/jbc.M116.773051. Epub 2017 May 3.

30.

Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients.

Clifton GT, Litton JK, Arrington K, Ponniah S, Ibrahim NK, Gall V, Alatrash G, Peoples GE, Mittendorf EA.

Ann Surg Oncol. 2017 Aug;24(8):2161-2167. doi: 10.1245/s10434-017-5844-0. Epub 2017 Mar 17.

31.

Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ, Hortobagyi GN.

CA Cancer J Clin. 2017 Jul 8;67(4):290-303. doi: 10.3322/caac.21393. Epub 2017 Mar 14. Erratum in: CA Cancer J Clin. 2017 Jul 8;67(4):345.

32.

Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy.

FitzSullivan E, Bassett RL, Kuerer HM, Mittendorf EA, Yi M, Hunt KK, Babiera GV, Caudle AS, Black DM, Bedrosian I, Reyna C, Teshome M, Meric-Bernstam F, Hwang R.

Ann Surg Oncol. 2017 Mar;24(3):652-659. doi: 10.1245/s10434-016-5605-5. Epub 2016 Oct 3.

33.

Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer.

Vila J, Teshome M, Tucker SL, Woodward WA, Chavez-MacGregor M, Hunt KK, Mittendorf EA.

Ann Surg. 2017 Mar;265(3):574-580. doi: 10.1097/SLA.0000000000001492.

PMID:
27735826
34.

Targeting Immune Checkpoints in Hematologic Malignancies.

Alatrash G, Daver N, Mittendorf EA.

Pharmacol Rev. 2016 Oct;68(4):1014-1025. Review.

35.

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence.

Mittendorf EA, Ardavanis A, Litton JK, Shumway NM, Hale DF, Murray JL, Perez SA, Ponniah S, Baxevanis CN, Papamichail M, Peoples GE.

Oncotarget. 2016 Oct 4;7(40):66192-66201. doi: 10.18632/oncotarget.11751.

36.

Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target.

Alatrash G, Garber HR, Zhang M, Sukhumalchandra P, Qiu Y, Jakher H, Perakis AA, Becker L, Yoo SY, Dwyer KC, Coombes K, Talukder AH, John LSS, Senyukov V, Lee DA, Sergeeva A, He H, Ma Q, Armistead PM, Roszik J, Mittendorf EA, Molldrem JJ, Hawke D, Lizee G, Kornblau SM.

Leukemia. 2017 Jan;31(1):234-237. doi: 10.1038/leu.2016.249. Epub 2016 Aug 30. No abstract available.

37.

Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer.

Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, Ueno NT, Hortobagyi GN, Chavez-MacGregor M.

Breast Cancer Res Treat. 2016 Sep;159(2):367-74. doi: 10.1007/s10549-016-3933-6. Epub 2016 Aug 13.

PMID:
27522517
38.

Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic Reconstruction.

Carter SA, Lyons GR, Kuerer HM, Bassett RL Jr, Oates S, Thompson A, Caudle AS, Mittendorf EA, Bedrosian I, Lucci A, DeSnyder SM, Babiera G, Yi M, Baumann DP, Clemens MW, Garvey PB, Hunt KK, Hwang RF.

Ann Surg Oncol. 2016 Oct;23(10):3190-8. doi: 10.1245/s10434-016-5407-9. Epub 2016 Jul 12.

PMID:
27406093
39.

Clinical Development of the E75 Vaccine in Breast Cancer.

Clifton GT, Gall V, Peoples GE, Mittendorf EA.

Breast Care (Basel). 2016 Apr;11(2):116-21. doi: 10.1159/000446097. Epub 2016 Apr 26. Review.

40.

Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer.

Vila J, Mittendorf EA, Farante G, Bassett RL, Veronesi P, Galimberti V, Peradze N, Stauder MC, Chavez-MacGregor M, Litton JF, Huo L, Kuerer HM, Hunt KK, Caudle AS.

Ann Surg Oncol. 2016 Oct;23(11):3501-3509. doi: 10.1245/s10434-016-5277-1. Epub 2016 May 23.

PMID:
27216742
41.

Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain.

Knutson KL, Clynes R, Shreeder B, Yeramian P, Kemp KP, Ballman K, Tenner KS, Erskine CL, Norton N, Northfelt D, Tan W, Calfa C, Pegram M, Mittendorf EA, Perez EA.

Cancer Res. 2016 Jul 1;76(13):3702-10. doi: 10.1158/0008-5472.CAN-15-3091. Epub 2016 Apr 20.

42.

Injecting Hope--A Review of Breast Cancer Vaccines.

Mittendorf EA, Peoples GE.

Oncology (Williston Park). 2016 May;30(5):475-81, 485. Review.

43.

Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells.

Chawla A, Alatrash G, Philips AV, Qiao N, Sukhumalchandra P, Kerros C, Diaconu I, Gall V, Neal S, Peters HL, Clise-Dwyer K, Molldrem JJ, Mittendorf EA.

Cancer Immunol Immunother. 2016 Jun;65(6):741-51. doi: 10.1007/s00262-016-1841-6. Epub 2016 Apr 29.

44.

The development and use of the E75 (HER2 369-377) peptide vaccine.

Clifton GT, Peoples GE, Mittendorf EA.

Future Oncol. 2016 Jun;12(11):1321-9. doi: 10.2217/fon-2015-0054. Epub 2016 Apr 5.

45.

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.

Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, Hale DF, Perez SA, Anastasopoulou EA, Pistamaltzian NF, Ponniah S, Baxevanis CN, von Hofe E, Papamichail M, Peoples GE.

Ann Oncol. 2016 Jul;27(7):1241-8. doi: 10.1093/annonc/mdw150. Epub 2016 Mar 30.

46.

The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment.

Mittendorf EA, Vila J, Tucker SL, Chavez-MacGregor M, Smith BD, Symmans WF, Sahin AA, Hortobagyi GN, Hunt KK.

JAMA Oncol. 2016 Jul 1;2(7):929-36. doi: 10.1001/jamaoncol.2015.6478.

47.

Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group.

Swisher SK, Wu Y, Castaneda CA, Lyons GR, Yang F, Tapia C, Wang X, Casavilca SA, Bassett R, Castillo M, Sahin A, Mittendorf EA.

Ann Surg Oncol. 2016 Jul;23(7):2242-8. doi: 10.1245/s10434-016-5173-8. Epub 2016 Mar 10.

PMID:
26965699
48.

Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.

McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F.

PLoS One. 2016 Mar 8;11(3):e0151121. doi: 10.1371/journal.pone.0151121. eCollection 2016. No abstract available.

49.

Obese Women Experience Fewer Complications after Oncoplastic Breast Repair following Partial Mastectomy Than after Immediate Total Breast Reconstruction.

Tong WM, Baumann DP, Villa MT, Mittendorf EA, Liu J, Robb GL, Kronowitz SJ, Garvey PB.

Plast Reconstr Surg. 2016 Mar;137(3):777-91. doi: 10.1097/01.prs.0000479939.69211.19.

PMID:
26910658
50.

Use of a Magnetic Tracer for Sentinel Lymph Node Detection in Early-Stage Breast Cancer Patients: A Meta-analysis.

Teshome M, Wei C, Hunt KK, Thompson A, Rodriguez K, Mittendorf EA.

Ann Surg Oncol. 2016 May;23(5):1508-14. doi: 10.1245/s10434-016-5135-1. Epub 2016 Feb 18.

PMID:
26893221

Supplemental Content

Loading ...
Support Center